ImmunityBio (IBRX) Other Non-Current Liabilities (2014 - 2026)

ImmunityBio (IBRX) has 12 years of Other Non-Current Liabilities data on file, last reported at $472000.0 in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 94.77% year-over-year to $472000.0 in Q1 2026; TTM through Mar 2026 was $472000.0, a 94.77% decrease from a year earlier, with the FY2025 full-year figure at $424000.0, up 32.92% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $472000.0, up from $424000.0 in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for IBRX reached as high as $65.4 million in Q2 2024 and fell as low as $288000.0 in Q1 2022.
• Historically, Other Non-Current Liabilities has averaged $11.8 million across 5 years, with a median of $710000.0 in 2025.
• Across the five-year window, Other Non-Current Liabilities surged 10264.58% in 2023 and tumbled 98.91% in 2025, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $21.6 million in 2022, then sank by 94.87% to $1.1 million in 2023, then slumped by 71.24% to $319000.0 in 2024, then jumped by 32.92% to $424000.0 in 2025, then increased by 11.32% to $472000.0 in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $472000.0 in Q1 2026, $424000.0 in Q4 2025, and $702000.0 in Q3 2025.